GRIFOLS

Grifols earns Platinum rating in EcoVadis sustainability assessment

- ***Grifols has earned the highest distinction – Platinum category – in the prestigious EcoVadis sustainability ranking, with a score of 86 our of 100 among companies evaluated worldwide***

- ***This recognition further strengthens Grifols' position as a global leader in sustainability, following its inclusion among the world's top biotechnology companies by the Dow Jones Best-in-Class indices***

- ***Grifols remains firmly committed to sustainable practices and has reinforced its strategic sustainability plan and 2030 Agenda this year***

Barcelona, October 23, 2025 - EcoVadis, one of the world's leading platforms for corporate sustainability ratings, has awarded Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leader in plasma-derived medicines, the highest distinction in its sustainability ranking.

This rating, the highest in Grifols' history with a score of 86 out of 100, underscores the company's progress in environmental, social, and governance (ESG) matters and highlights the strength of its strategy to integrate sustainability across its business model, global operations and supplier network.

Over the past two years, Grifols had been awarded the Gold Medal for Excellence in Sustainability. This year, the company has been elevated to the Platinum category, an honor reserved for only 1% of the approximately 50,000 companies assessed by EcoVadis globally.

EcoVadis medals evaluate the strength of a company's management system based on sustainability criteria and its performance relative to other companies in the EcoVadis database over the past 12 months.

This year, Grifols stood out with a score of 92 out of 100 in the environmental category and showed significant improvement in labor practices and human rights, increasing its score from 80 to 87. The most notable progress was in the area of sustainable procurement, where the company's score rose from 60 to 79 out of 100, reflecting Grifols' commitment to transforming its value chain.

Grifols regularly reviews its evaluation, collaboration, and development processes with strategic suppliers to ensure its operations align with environmental, social, and ethical standards. This approach helps reduce risks and promotes transparency and innovation across its supply network.

Additionally, the company's ethics score increased from 70 to 81 out of 100, highlighting the strengthening of its culture of compliance, transparency, and governance.

Raimon Grifols, Vice Chairman of Grifols and member of the Board's Sustainability, Communication and Reputation Committee, stated: "Sustainability is a non-negotiable pillar of our company. Since our founding more than 115 years ago, it has been part of our DNA. Today, we are especially grateful for this global recognition from such a prestigious platform as EcoVadis."

This achievement adds to a series of recent accolades that position Grifols among the top-performing companies in sustainability. In 2024, the company ranked among the leading biotechnology firms in the Dow Jones Best-in-Class Indices (formerly DJSI), being included for the fourth and fifth consecutive years in the World and Europe indices, respectively.

Grifols also earned the Prime badge in ISS's ESG rating, received a BBB rating from MSCI ESG Ratings, and was ranked among the best-performing companies by Sustainalytics, with a low ESG risk score. The company also participates annually in the Carbon Disclosure Project (CDP) and has been part of the FTSE4Good Index since 2018.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non- voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office
media@grifols.com
Tel. +34 93 571 00 02

INVESTORS:

Investors Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval